The Romanian Competition Council fines a pharmaceutical producer and three distributors for participation into a market-sharing cartel active on the insulin market (Eli Lilly Export, A&A Medical, Mediplus Exim and Relad Pharma)

Following an investigation initiated in July 2005 and which has lasted for almost 3 years, the Romanian Competition Council (RCC) has fined one pharmaceutical producer and three distributors for participation into a market-sharing cartel active between April 2003 and May 2005, imposing fines in a total amount of Euro 22.7 million (RON 83.6 million). At the same time, the RCC ascertained the breach of the law by the Ministry of Public Health. At the auction within the Diabetic National Program in 2003, the products of Eli Lilly were offered through the three distributors, each authorized to participate with different products, so that they did not compete against each other in the auction. Following the auction minutes mentioning that the auction will be organized again, all three

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Nestor Nestor Diculescu Kingston Petersen (Bucharest)

Quotation

Georgeta Harapcea, The Romanian Competition Council fines a pharmaceutical producer and three distributors for participation into a market-sharing cartel active on the insulin market (Eli Lilly Export, A&A Medical, Mediplus Exim and Relad Pharma), 12 March 2008, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 19850

Visites 6511

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues